$1.6BStrategic acquisitionHealthcare & Life Sciences

Viatris to buy Pacira BioSciences for $1.65B in cash

Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion. Pacira sells the non-opioid pain drugs EXPAREL and ZILRETTA and generated about $746 million in revenue and $177 million in adjusted EBITDA over the last twelve months.

Why it matters: The deal adds patent-protected, high-margin U.S. products to Viatris's push into innovative medicines and makes it a leader in non-opioid pain management.

Read the full coverage, free

Read at PR NewswireFree

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals

$5.8BTake-privateHealthcare & Life SciencesOct 8, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Option Care Health agreed to be acquired by private equity firm CD&R and drug distributor McKesson for $32.05 per share in cash. The deal values the home and alternate-site infusion provider at about $5.8 billion. The offer is a roughly 37% premium to Option Care's October 5 closing price.

Read at Yahoo FinanceFree

UndisclosedDivestiture / carve-outHealthcare & Life SciencesOct 8, 2026

Medtronic sets 4.5939 ratio for MiniMed split-off

Medtronic set the final exchange ratio at 4.5939 MiniMed shares per Medtronic share in its exchange offer to split off MiniMed Group.

Read at PR NewswireFree

UndisclosedStrategic acquisitionHealthcare & Life SciencesCompletedOct 8, 2026

AmyriAD buys Recognify Life Sciences in all-share deal

AmyriAD Therapeutics acquired Recognify and its cognition drug RL-007 in an all-share transaction.

Read at PR NewswireFree

200 employeesStrategic acquisitionHealthcare & Life SciencesCompletedOct 8, 2026

Integrity Care Group buys 15 NextCare clinics

Integrity Care Group acquired 15 NextCare urgent care clinics in Oklahoma, Missouri and Nebraska, reaching 100 locations.

Read at GlobeNewswireFree